



FORM PTO-1009 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4102-1	SERIAL NO. 09/163,089
	APPLICANT McKENZIE et al.	
	FILING DATE September 29, 1998	GROUP ART 1631

RECEIVED

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
EE	1	4,720,386	1/1988	McCollester	424	88	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
EE	2	4187689	3/1990	Australia	—	—		
	3	0326111	1989	EPO	—	—		
	4	0308147	3/1989	EPO	—	—		
	5	2279422	3/1976	France	—	—		
	6	46-016913	1/1971	Japan	—	—		
	7	61-112023	5/1986	Japan	—	—		
	8	01233219	9/1993	Japan	—	—		
	9	05246860	9/1993	Japan	—	—		
	10	WO8908711	9/1989	PCT	—	—		
	11	WO9211033	7/1992	PCT	—	—		
	12	WO9306858	4/1993	PCT	—	—		
	13	WO9314195	7/1993	PCT	—	—		
	14	WO9317712	9/1993	PCT	—	—		
4	15	WO9406916	3/1994	PCT	—	—		
EE	16	WO9413312	6/1994	PCT	—	—		

EXAMINER <i>Robert Zeman</i>	DATE CONSIDERED 7/26/02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 4102-1	SERIAL NO. 09/163,089
	APPLICANT McKENZIE et al.	
	FILING DATE September 29, 1998	GROUP ART 1631

## OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

17	Ads in fundamentals of Immunology 2nd Ed. Chapter 36 pp. 985-1032 William Paul Ed.
18	Apostolopoulos et al., <i>Br. J. Cancer</i> , 67:713-720 (1993)
19	Barnd et al., <i>Proc. Natl. Acad. Sci. USA</i> , 86:7159-7163 (1989)
20	Denton, <i>Cancer Letters</i> , 70:143-150 (1993)
21	Devine et al., <i>Cancer Research</i> , 51:5826-5836 (1991)
22	Ellis, Chapter 29 in <i>Vaccines</i> Plotkin et al. Eds. W B Saunders Co. Philadelphia 1988, pp. 568-575
23	Fentonot et al., <i>Cancer Research</i> , 53:5386-5394 (1993)
24	Hanisch et al., <i>J. Biol. Chem.</i> , 264:872-883 (1989)
25	Hudecz et al., <i>J. Immunol. Meth.</i> , 147:201-210 (1992)
26	Jerome et al., <i>Cancer Research</i> , 52:5985-5990 (1992)
27	Karanikas et al., <i>J. Clin. Invest.</i> , 100:2783-2792 (1997)
28	Lalani et al., <i>J. Biol. Chem.</i> , 266:15420-15426 (1991)
29	Langsdale, <i>Inpharma Weekly</i> , 915:3-4 (1993)
30	Lei et al., <i>Cancer Immunology Immunotherapy</i> , 36:9-17 (1993)
31	McCool et al., <i>Biochem. J.</i> , 267:491-500 (1990)
32	Mitchell, <i>J. Natl. Cancer Institute</i> , 87:949-951 (1995)
33	Nurmukhamedov et al., <i>Immunologiya</i> , 4:61-63 (1991) (see English abstract at p. 63)
34	Okawa et al., <i>J. Immunol. Meth.</i> , 149:127-31 (1992)
35	Okawa et al., <i>J. Immunol. Meth.</i> , 149:127-131 (1992)
36	Scholm et al., <i>Breast Cancer Research &amp; Treatments</i> , 38:27-39 (1996)
37	Tsang et al., <i>J. Natl. Cancer Institute</i> , 87:982-990 (1995)

RECEIVED

APR 18 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.